s managed care organizations continue to report doubledigit increases in pharmacy-related expenditures, shifting some of the cost of prescription medications to consumers has become a growing trend in the management of pharmaceutical benefits. 1 Multi-tiered pharmacy benefit plans have become a very popular structure in pharmacy benefits primarily as 2-and 3-tier plans. In 2-tier plans, the lower copayment amount is generally for formulary-based generic medications, and the higher copayment amount is for brand-name medications. Typical copayment amounts are $5 to $15 for generic (first-tier) medications and $10 to $30 for formulary, brand-name (secondtier) medications. Nonformulary medications can be obtained at the brand copayment amount, sometimes requiring health plan approval through prior authorization.
The 3-tier drug plan design is being adopted rapidly by managed care plans and is replacing the 2-tier plan design. 2 Generally, 3-tier, like 2-tier plans, have the lowest copayment amount for generic formulary medications. The second copay tier applies to formulary brand-name medications, while the highest copayment, or the "third tier," is usually reserved for nonformulary medications and can range between $30 and $50. 3 Three-tier plans allow members to have a choice in their drug therapy needs if they are willing to pay for that choice. 2 The implementation of 3-tier plans may be followed by a variety of responses from patients, depending on their financial resources, health status, and perceived health benefits. 4 Patients may choose to switch to a generic or alternative brand-name medication in a less-expensive copay tier, or they may choose to pay the higher copayment for a third-tier drug. This decision may be based on a variety of factors such as satisfaction with the current therapy, the disease being treated, perceptions about the similarity of lower-tier substitutes, and personal financial resources. Other possible patient responses to conserve personal financial resources include reduction in dose frequency to reduce refill frequency or premature discontinuation of the medication. A main concern regarding 3 tier pharmacy benefit plans is that the increased amount of cost sharing may restrict access to medications for vulnerable populations such as those with chronic disease states. However, employers are rapidly adopting 3-tier pharmacy benefit plans for their employees to offset their own increasing costs of health care, and recent trends suggest that the copayment amounts for 3-tier plans will continue to increase. 5 While there has been some research that examines the impact of 3-tier plans on pharmaceutical, medical care utilization, and expenditures, there is little evidence regarding member attitudes and satisfaction regarding their 3-tier pharmacy A
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OBJECTIVE: To evaluate the effects of 2-and 3-tiered pharmacy benefit plans on member attitudes regarding their pharmacy benefits.
METHODS: We performed a mail survey and cross-sectional comparison of the outcome variables in a large managed care population in the western United States. Participants were persons with chronic disease states who were in 2-or 3-tier copay drug plans. A random sample of 10,662 was selected from a total of 25,008 members who had received 2 or more prescriptions for a drug commonly used to treat one of 5 conditions: hypertension, diabetes, dyslipidemia, gastroesophageal reflux disease (GERD), or arthritis. Statistical analysis included bivariate comparisons and regression analysis of the factors affecting member attitudes, including satisfaction, loyalty, health plan choices, and willingness to pay a higher out-ofpocket cost for medications.
RESULTS: A response rate of 35.8% was obtained from continuously enrolled plan members. Respondents were older, sicker, and consumed more prescriptions than nonrespondents. There were significant differences in age and health plan characteristics between 2-and 3-tier plan members: respondents aged 65 or older represented 11.7% of 2-tier plan members and 54.7% of 3-tier plan members, and 10.0% of 2-tier plan members were in Medicare+Choice plans versus 61.4% in Medicare+Choice plans for 3-tier plan members (P<0.05). Controlling for demographic characteristics, number of comorbidities, and the cost of health care, 2-tier plan members were more satisfied with their plan, more likely to recommend their plan to others, and less likely to switch their current plans to obtain better prescription drug coverage than 3-tier plan members. While members were willing to purchase higher cost nonformulary and brand-name medications, in general, they were not willing to pay more than $10 (in addition to their copayment amount) for these medications. Older respondents and sicker individuals (those with higher scores on the Chronic Disease Indicator) appeared to have more positive attitudes toward their pharmacy benefit plans in general. Higher reported incomes by respondents were also associated with greater satisfaction with prescription drug coverage and increased loyalty toward the pharmacy benefit plan. Conversely, the more individuals spent for either their health care or prescription medications, the less satisfied they were with their prescription drug coverage and less loyalty they appeared to have for their health plans. An inverse relationship also appeared to exist between the out-of-pocket costs for prescription medications and members' willingness to pay for nonformulary medications.
CONCLUSIONS: Three-tier members had lower reported satisfaction with their plans compared to members in 2-tier plans. The financial resources available to members (which may be a function of being older and having more education and higher incomes), the number of chronic disease states that members have, and other factors may influence their attitudes toward their prescription drug coverage. 6 Member attitudes and, in particular, member satisfaction are becoming an important criterion by which the quality of a health plan is evaluated. For example, the Consumer Assessment of Health Plans survey compares member satisfaction among health plans serving Medicare beneficiaries and is used as a measure of quality among competing Medicare+Choice plans. 7 There has been limited research on member attitudes regarding prescription drug coverage. Desselle conducted a general examination of member satisfaction with prescription drug plans and found that respondents were very satisfied with the quality of their prescription drug plan. 8 Satisfaction was primarily determined by perceptions about coverage limitations and having a choice of health plans. 8 Most recently, Holdford et al. found that having a choice of medications and copayment amounts that patients were responsible for were the 2 most important attributes cited by individuals in selecting their prescription drug coverage. 9 However, an evaluation regarding member attitudes about their prescription drug coverage needs to go beyond member satisfaction. Attitudes about health plan choice and the willingness to pay for these higher-priced medications are examples of member perceptions that may provide some insight into the utility of 3-tier plans in influencing member behavior.
Analysis of health-plan switching behavior has shown that the provision of information about the quality of a health plan has a small effect on consumer plan choices, and employees were more likely to switch from health plans with lower reports of quality to plans that received higher ratings of quality. 10 As consumers have repeatedly stated, the cost of health care is always one of the most important pieces of information used to make health plan choices. The increasing out-of-pocket costs of prescription medications in a 3-tier plan may influence their health plan choices. 11, 12 Therefore, attitudes of members such as willingness to switch health plans for better prescription drug coverage, recommend their pharmacy benefit plan to others, or choose a health plan based on the composition of its formulary are important aspects of member attitudes that need to be evaluated. 9, 13 In addition to member attitudes about their prescription drug plans, their perceptions regarding higher-cost medications such as formulary versus nonformulary medications and, within the former, the lower-cost generic versus the higher-cost brand-name medications, may influence their prescription choices. For example, member perceptions about the equivalence of brand and generic medications have been reported, with individuals requiring greater cost savings to purchase generic medications for some disease states, such as heart disease, over others. 14 Finally, in 3-tier copay plans, the cost of medications to the members increases for each successive copay tier. Brand-name medications have a higher copay cost than generic drugs, and nonformulary medications have a higher copay cost than formulary, brand-name medications. An assessment of how much more members are willing to pay for these medications may provide employers and managed care decision makers with important information about their subsequent prescriptionpurchasing behavior. One method of assessing the willingness to pay is to survey individual preferences when hypothetical situations are posed. 15 While consumers have expressed a desire to pay for pharmacist-related services, mean amounts have been small, ranging from $1 to $5 per prescription and, on average, between $15 and $30 for a set of pharmacist-provided services. [16] [17] [18] While this research has looked at pharmacist-related services, little is known about how price-sensitive members are when purchasing their prescribed medications.
In addition, the characteristics of individuals that influence their willingness to pay for prescription medications have also remained unknown. 19 Therefore, it remains to be seen what the most frequent willingness-to-pay amounts are for nonformulary and brand-name medications, and what characteristics of the members themselves influence their responses.
To better understand the issues outlined above, the overall purpose of this study was to measure various member attitudes regarding multi-tiered pharmacy benefit plans. Specific objectives were to assess member satisfaction, loyalty, and the willingness to pay higher copays for medications and the relationship between sociodemographic characteristics, cost of health care, and pharmacy plan type to these attitudes.
■■ Methods Study Sample
The study used a cross-sectional mail survey design that targeted enrollees of a large managed care organization in the western United States. The goal of sample selection was to obtain a representative group of plan members in 2-and 3-tier pharmacy benefit plans who would be most affected by variations in cost sharing. Five chronic disease states were chosen for prescription medications deemed important to health; i.e., those medications whose withdrawal could have serious effects on health outcomes. 20 The 5 disease states chosen were hypertension, diabetes, dyslipidemia, gastroesophageal reflux disease (GERD), and arthritis. Pharmacy claims data were used for sample selection. The study sample was identified in 2 steps: first, a random sample of 25,008 individuals who had at least 2 prescriptions for one of the 5 disease states of interest in calendar year 2000 and who were enrolled in a 2-or 3-tier plan for retail prescriptions in 2000 were identified. A variety of 2-and 3-tier plans were represented in the sample. The selected individuals were enrolled in a health maintenance organization (HMO), preferred provider organization (PPO), or Medicare+Choice managed care plan. Medicare+Choice individuals in the 3-tier plans had an annual benefit maximum of $1,000 at the time of the study. All of these individuals were mailed a survey. The sample subsequently was narrowed to include just the 10,662 individuals who were continuously enrolled in the plan between January 1, 2000, and December 31, 2000. This was done to enable the collection of data on the number of comorbidities such as the Chronic Disease Indicator (CDI) score for individuals (described in the next section) and to enable comparisons of survey respondents and nonrespondents on medication utilization characteristics.
Comparisons of the continuously enrolled sample to those who disenrolled from their health plan at the end of 2000 were conducted on age, gender, pharmacy plan type, managed care plan (HMO, PPO, or Medicare+Choice) and income (using median household income from the 2000 U.S. Census data), using a likelihood ratio chi-square test of equal proportions. Although tests of difference were statistically significant for some of the characteristics (age, gender, and income where P<0.05), the mean values of age (53 years for both groups), and income ($50,376 for the continuously enrolled and $50,550 for the disenrolled) and distribution of gender (49% males for the continuously enrolled and 47% for those who disenrolled) in the 2 groups were similar and may be attributed to the large sample sizes employed in the study (10, 662 for the continuously enrolled and 14,346 for the disenrolled sample).
Study Measures
The relevant study items, which were part of a larger questionnaire, are provided in the Appendix and described, in part, below.
General attitudes about satisfaction with prescription drug coverage were assessed by asking respondents to indicate how satisfied they were with various statements related to cost sharing, access to prescription medications, information about pharmacy benefits, and location of pharmacies such as "amount you pay for prescription medications" or "ability to get any medication prescribed by your doctor." A 7-point Likert-type scale, where 1 was "dissatisfied" and 7 was "satisfied," was used to measure general attitudes about prescription drug coverage. A "not applicable" choice was also provided.
Information sources used by members in making decisions about prescription use were also assessed. Respondents were asked when a physician prescribes a new medication how likely they were to use the following information sources before purchasing the medication: second opinion from another physician; consulting with a pharmacist, friends, family, or coworkers with similar health insurance plans; looking up information on the Internet, magazines, or reference books; and looking up the cost of the medication. Respondents were asked to indicate their response on a 7-point scale, where 1 was "very unlikely" and 7 was "very likely."
Outcome measures related to member satisfaction and loyalty about their prescription drug coverage were also assessed. 13 The first item was member satisfaction with their prescription drug coverage. Respondents were asked to rate their experiences on a scale of 0 to 10, where 0 is the worst possible and 10 is the best possible coverage. The second item was the likelihood of switching health plans to obtain better prescription drug coverage. The third item was the likelihood of recommending current prescription drug coverage to others. The fourth item was the likelihood of selecting a health plan based on availability of their medications on the health plan' s formulary. For the second, third, and fourth items, respondents were asked to indicate their response on a 5-point scale, where 1 was "very unlikely" and 5 was "very likely."
Two measures assessed the willingness of members to pay extra to purchase higher cost medications such as nonformulary (third-"tier") and brand-name (second-"tier") medications. The survey items were (1) If your doctor prescribes a brandname medication but there is a generic medication available that would cost you less, how much more would you be willing to pay to get the brand-name medication? and (2) If a medication that you have been taking regularly is nonformulary, how much more do you think you would be willing to pay per month to stay on the medication? The response scale for both items was $0, $1-$5, $6-$10, $11-$15, $16-$20, and >$20. The response scales on items were reverse-scored, when needed, to ease the interpretation of results.
Chi-square analysis was used to examine differences in categorical variables and the independent samples t test was used to examine differences for continuous measures. Statistical analyses were conducted using SPSS version 10.0 and the significance level was specified as P<.05. 21 Ordinary least squares and ordinal regression multivariate models were used to yield parameter estimates by pharmacy plan type (2-tier versus 3-tier) and other factors for ratings of each of the satisfaction, loyalty, and willingness-to-pay measures detailed above. To truly understand the differences between the 2 groups with regard to overall satisfaction with prescription drug coverage and the other outcome measures detailed above, relevant characteristics of the patient population, which may include demographic factors and health status measures, need to be taken into account as well to get more accurate estimates. Therefore, characteristics of the members themselves that were controlled in the multivariate models included the following: age, gender, employment status, pharmacy plan type, education, race, income, and number of comorbidities measured by the CDI. The CDI approximates the number of chronic diseases for each patient from pharmacy claims data by using an expert panel to determine if specific medication classes are indicative of a particular disease state. 22 Higher CDI scores indicate a greater number of chronic illnesses. Other measures included the total amounts paid per month for prescription medications and health plan premiums by the respondents, willingness to purchase a formulary medication when prescribed a nonformulary medication, likelihood of purchasing a brand-name medication when prescribed a generic medication, and the perceived equivalence between brand-name and generic medications.
The survey instrument was based on a comprehensive liter-ature review supplemented with 2 focus group meetings using a representative subset of individuals from the study sample. Individuals who participated in the focus groups were asked about their comprehension of pharmacy benefit terminology, concerns about their pharmacy benefit plans, factors affecting their access to medications, and their price sensitivity for higher-cost medications. The responses obtained from the focus group participants were used to develop the survey. To help respondents understand the survey, terms such as formulary and copayment were defined in the survey. The instrument was Median household income †
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Average monthly copayment amount per member pretested on a sample of 300 individuals (from a similar subset of the study sample), and modifications such as wording changes to questions, simplifying skip patterns of questions, and improving the overall flow of the instrument were made based on the results of the pretest. The survey instrument, along with a cover letter describing the study, was mailed to the remainder of the study sample in November 2000.
■■ Results Demographic Characteristics of the Sample
A total of 3,816 usable surveys (35.8%) were received from the sample of 10,662 members continuously enrolled during 2000, of which 2,316 individuals were in 2-tier plans and 1,499 in 3-tier plans (Table 1 ). There were varying structures of 2-and 3-tier pharmacy benefit structures represented in the study sample. The predominant 2-tier pharmacy benefit structure was a $7/$15 2-tier plan and a $15/$25/$40 3-tier plan. For members in 2-tier pharmacy benefit structure, half of the sample (53%) was in the $7/$15 plan, a little over a fourth (27%) was in a $5/$15 plan, and the remaining fifth (20%) was in a $5/$10 plan. For individuals in the 3-tier plan, more than three fourths of the sample (85%) was in a $15/$25/$40 plan, while the remaining 15% was in a $20/$35/$50 plan. Mail-order copayments for this sample were twice the amounts of the community pharmacy copayments, by tier, for a supply up to 90 days.
A majority of the respondents (87%) were white, with similar gender distributions in both plan types. Two-tier plan members appeared to be more educated, with higher incomes, and were more likely to be working full time compared to 3-tier plan members. Three-tier plan members were older and were more likely to be retired or not employed. More than half (54.7%) of the individuals in 3-tier plans were Medicare+Choice members versus 11.7% of 2-tier drug plan members in Medicare+Choice plans.
Three-tier plan members also appeared to pay more for their prescription medications per month (not shown), with 51.2% paying more than $50 per month, while 52.8% of 2-tier members paid less than $50 per month. However 2-tier plan members appeared to pay a higher premium per month for their health plan, with 40.5% paying between $100 and $300 or more per month, while a majority of the 3-tier members (49.7%) paid between $25 and $100 per month (possibly because the premium for Medicare+Choice members, which represented a third of the sample, was $69 per month). Threetier plan members purchased more prescriptions for themselves and their family per month (mean=5.60, SD=±2.8) than 2-tier plan members (mean=4.61, SD=±2.7) and also had more chronic disease states according to the CDI scores (mean=3.93, SD=±2.4) than 2-tier plan members (mean=3.27, SD=±2.3).
Comparison of Survey Respondents and Nonrespondents
To check for potential response bias, survey respondents and nonrespondents were compared on available demographic, medication utilization, and prescription expenditure characteristics (Table 2) . Survey respondents were older and more likely to be single, though there were no gender or income-level differences between the 2 groups. A greater number of survey respondents were in 2-tier plans, a third of whom were also Medicare+Choice members. More than half the respondents were single and had, on average, more disease states (3.6 versus 3.3) than nonrespondents. There were also more individuals taking antihypertensives and lipid-lowering agents among the survey respondents. Both respondents and nonrespondents had similar generic use and formulary compliance rates (although formulary compliance rates were statistically significant at P<0.05, these differences may be attributed to the large sample size). Respondents also consumed more prescriptions per month than nonrespondents and had higher prescription costs, although their cost-sharing amounts appeared to be similar. Thus, it appears that the survey respondents may represent an older and sicker group of individuals who may have higher and more expensive prescription use than the nonrespondents and, therefore, chose to respond to the survey.
Impact of Multi-tiered Pharmacy Benefits on Attitudes of Plan Members With Chronic Disease States
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General Attitudes About Prescription Drug Coverage
There were no differences between members in 2-and 3-tier plans regarding some dimensions of overall satisfaction with their pharmacy benefit plan, namely, access to any prescription medication, ease of obtaining information about benefits, or the health plan' s promptness in resolving disputes (Table 3) . Members in both plan types appeared to be moderately to very satisfied with these aspects. Two-tier plan members were more satisfied with the amount they pay for prescription medications (mean=4.37, SD=±1.77 versus mean=3.75, SD=±1.67 for 3-tier members). Of lesser practical significance perhaps was the finding that 2-tier plan members were more satisfied with the effort it takes to get prescription medications through their health plan (mean=5.34, SD=±1.71 versus mean=5.11, SD=±1.80 for 3-tier members). Table 4 shows that while there were some statistical differences in member' s responses from both groups to the informational influences on their decision-making process, the practical significance of these differences may not be important. For example, members were most likely to seek information about their prescription medications from the Internet (mean=3.55, SD=±1.80), magazines or reference books (mean=3.50, SD=±2.30), and consulting with a pharmacist (mean=3.22, SD=±2.0). Although members, in general, were less likely to get a second opinion from another physician about their prescribed medication, 2-tier plan members appeared to be more likely to do so than 3-tier plan members. Similarly, they were more likely to consult with friends and family than 3-tier plan members. However, 3-tier plan members were more likely to look up the cost of their medication than 2-tier plan members.
Information Sources Used by Members in Making Decisions About Prescription Use
Member Satisfaction and Loyalty Regarding Their Prescription Drug Coverage
Overall, members appear to be moderately satisfied with their prescription drug coverage (mean=5.52, SD=±2.14). Controlling for the differences in demographic factors, number of comorbidities, and member cost-sharing amounts for health .034* care and prescription medications, there appeared to be differences between 2-and 3-tier plan members regarding attitudes about prescription drug coverage. Three-tier plan members were 10.5% less satisfied than 2-tier members with their prescription drug coverage (Table 5) . Individuals who were 65 years or older were 13.3% more satisfied with their prescription drug coverage than younger individuals (those between 18 and 45 years). Member income was also related to satisfaction, suggesting that those with higher incomes may report greater satisfaction with their prescription drug coverage. For example, individuals with income levels between $35,000 and $49,999 and those with incomes above $65,000 were 6.2% and 5.2% more satisfied, respectively, with their prescription drug coverage than those with lower incomes ($0 to $24,999). Individuals with a higher score on the Chronic Disease Indicator also reported higher satisfaction with their prescription drug coverage. Finally, the more individuals paid for their health plan premium and prescription medications per month, the less satisfied they were with their prescription drug coverage. In general, although members were somewhat neutral about switching their current health plan (mean=3.1, SD=±1.44) to obtain better prescription drug coverage, 3-tier plan members were 10.5% more likely to do so than 2-tier plan members. Age was related to the likelihood of switching health plans; individuals between the ages of 56 and 64 years were 7.9% less likely and those over the age of 65 were 8.8% less likely to change health plans for better prescription drug coverage than younger individuals (those between 18 and 45 years). A trend between higher income levels and a lower likelihood of changing health plans to obtain better prescription drug coverage was also observed. Individuals with a higher score on the CDI were less likely to switch their heath plans. The more individuals paid for their health plan premium and prescription medications per month, the more likely they were to switch health plans.
* Independent samples t test at P<.05. Scale = 1-7, with 1= very unlikely and 7 = very likely. Respondents were asked, "When a doctor prescribes a new medication, how likely were you to use the following information sources before purchasing the medication?"
Three-tier plan members were 9.6% less likely to recommend their prescription drug coverage to coworkers and friends compared to 2-tier plan members (mean=3.2, SD=±1.30). Among older individuals, those between the ages of 56 and 64 years were 5.6% more likely and those over the age of 65 years were 10.7% more likely to recommend their prescription drug coverage to others than those between the ages of 18 and 45 years.
Individuals with higher incomes appeared to be more likely to recommend their prescription drug coverage to others. Individuals with a college or graduate education were also approximately 4% less likely to recommend their prescription drug coverage to others than those with a high school (and some post-high school) education. Individuals with a higher score on the CDI were more likely to recommend their prescription drug coverage to others. Finally, the more individuals paid for their health plan and prescription medications per month, the less likely they were to make recommendations about their prescription drug coverage.
No differences in pharmacy plan type were observed in the likelihood of members selecting a health plan based on the availability of medications on the health plan' s formulary. In gen- eral, members were likely to choose a health plan based on its formulary content (mean=4.2, SD=±1.12). Those who had some graduate education were 7.2% less likely to choose their health plan based on this criterion than those with a high school (and some post-high school) education. The more individuals paid for their prescription medications per month and the greater the number of chronic disease states they had (as measured by the CDI) the more likely they were to choose a health plan based on whether their prescription medications were on the formulary. Figure 1 shows that approximately a third of the respondents stated that they were not willing to pay anything extra to purchase their nonformulary medication, a third were willing to pay between $1 and $5, and only a fourth were willing to pay between $6 and $10. Thus, 83% of the respondents reported that they were not willing to pay more than $10 extra per month to purchase a nonformulary medication. No statistically significant differences between 2-and 3-tier plan members were observed. .018
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. When examining the factors that influence the willingness to pay extra for a nonformulary medication, Table 6 shows that individuals who stated that they were likely to switch to a formulary medication if taking a nonformulary medication were less willing to pay more per month for their nonformulary medication. Similarly, those with graduate education were also more likely to be in the higher categories than those with lesser education. One of the income categories ($0 to $24,999) was also a statistically significant predictor of the outcome variable, although the practical significance of this relationship is not clear.
Similar results were obtained in assessing the willingness to pay more for a brand-name medication when prescribed a generic medication (model results are not shown). Figure 2 shows that approximately one half of the respondents stated that they were not willing to pay anything extra for a prescribed brand-name medication when a generic alternative was available.
Members who stated that they were likely to purchase a generic medication when prescribed a brand-name medication and those who considered brand-name generic medications to be equivalent were less likely to be willing to pay more for the brandname medication than those who had higher scores on these measures. As in the previous model, those with graduate education were also more likely to be willing to pay higher amounts for brandname medications than those with less education.
■■ Discussion
Findings regarding member satisfaction with their pharmacy benefit plan corroborate to some extent those of previous studies and support the proposed hypotheses. 8 Mean satisfaction scores with prescription drug coverage were between 5 and 6 on a 10-point scale suggesting that, in general, overall satisfaction with pharmacy benefit plans is not very high. However, this sample represented individuals with chronic disease states enrolled in managed care plans; previous work found lower satisfaction with health care among persons with chronic disease enrolled in managed care plans compared to those in traditional fee-for-service plans. 23 One possible explanation that might mediate the relationship between satisfaction and chronic illness in managed care plans may be that, due to the nature of their illnesses, members with chronic illness may be more aware of their health care and pharmacy benefits, in particular, the cost-control mechanisms such as multi-tier copay plan designs. Hence, they may be less satisfied with their prescription drug coverage.
The results of this study show that clearly there are differences in perceptions of members in 2-and 3-tier copay plans regarding their prescription drug coverage. Specifically 2-tier plan members are more satisfied with their cost-sharing amounts than 3-tier members. Members in 3-tier plans appear to be more concerned about the cost of their medication and are more likely to look it up than their 2-tier counterparts. Controlling for the differences in demographic factors, number of comorbidities, and member cost-sharing amounts for health care and prescription medications, members in 2-tier plans are more satisfied with their plan, more likely to recommend their plan to others, and less likely to switch their current health plan to obtain better prescription drug coverage than those in 3-tier plans. These findings corroborate, to some extent, those of previous studies, where individuals with higher out-of-pocket costs have reported lower satisfaction levels with their health plan as well. [24] [25] [26] Also, it has been seen that, in general, individuals with chronic disease states have reported lower satisfaction with the cost of medical care than healthy enrollees of managed care organizations. 23 These findings support, to some extent, the importance of copayments as a determinant of member satisfaction with their health plans. Holdford et al. found that higher copayment amounts were associated with a lower preference for prescription drug plans, and increasing the copayment from $8 to $15 had 3 times more impact on consumer preference than increasing it from $0 to $8. 9 The findings may be, in part, attributed to the characteristics of the 2-tier plan members represented in this sample. This group appeared to be a younger, working group of individuals with higher incomes and in a better state of health than 3-tier plan members. Medicare+Choice members were overrepresented in the 3-tier drug plans. (Table 1 ) These individuals are older, retired, or not employed, with greater medication use, greater number of comorbidities, and they represent a population that would be more likely to be vulnerable to the increased costsharing effects of 3-tier plans. About 55% of the 3-tier plan members were older than 65 years, and only 12% of the 2-tier plan members were in the similar age category. Thus, it may be expected that prescription utilization may be higher for the 3-tier plan members, and they may have more experience with their medical and pharmacy benefits than those in 2-tier plans. These differences in age and, subsequently, prescription purchasing behaviors between the 2-and 3-tier groups may explain some of the responses related to satisfaction with cost-sharing amounts (Table 3 ) and the propensity to look up the cost of medications (Table 4) .
However, older respondents and sicker individuals (those with higher scores on the CDI) appeared to have more positive attitudes toward their pharmacy benefit plans in general. In a similar finding, Desselle found that those aged 60 or older were more satisfied with their prescription drug coverage than younger individuals. 27 Although a correlation between better health status and member satisfaction has been observed, the inverse relationship found in this study may, in part, be due to the nature of the older population represented in the extant study sample, a third of whom were Medicare members. 27 Medicare+Choice members have reported higher satisfaction with the costs of care compared to nonmanaged care individuals. 28 One explanation for this finding may be that the Medicare+Choice population, in general, has little access to prescription drug coverage, and any access provided through managed care plans, however limited, might contribute to member satisfaction. 24 Higher incomes were also associated with greater satisfaction with prescription drug coverage and increased loyalty toward the pharmacy benefit plan. It is possible that individuals with higher incomes are less price-sensitive to cost-sharing amounts, both for prescription medications and medical care and, hence, have more positive feelings about their prescription drug coverage in general than those with lower incomes.
Conversely, the more individuals spent for either their health care or prescription medications, the less satisfied they were with their prescription drug coverage and the less loyalty they appeared to have for their health plans. 29 An inverse relationship exists between the out-of-pocket costs for prescription medications and members' willingness to pay for nonformulary medications. This is an intuitive finding since individuals confronted with higher out-of-pocket costs are likely to be more pricesensitive. While income has been shown to be associated with the willingness to pay for medical care in past research, in this study, the education levels of the respondents could be a proxy for income: those with lower education levels were less willing to pay for brand-name or nonformulary medications compared to those with a higher education. 17, 30 Both 2-and 3-tier pharmacy plan members expressed similar opinions about their willingness to purchase lower-cost medications, but a majority of the sample were reluctant to pay more than $10 more per month (in addition to their copayment) to stay on either a brand-name or a nonformulary medication that they had been using regularly when there was a less expensive alternative available. A low threshold for willingness to pay for pharmacy services, in general, has been demonstrated. In a field experiment comparing hypothetical and real purchase decisions for a pharmacist-oriented asthma management program, a majority of the sample that purchased the program did so at the lowest offered price of $15. 18 Thus, it appears the same holds true for prescription medications where the willingness to pay threshold for a majority of this sample is under $10. As some evidence of this finding, there has been some research to show that when confronted with increases in cost sharing for prescription medications, members are willing to try lower-cost alternatives. 31 Member satisfaction also appears to be related to the amount of cost sharing. In a recent study, members in prescription drug plans with a $1 to $5 copayment for brand-name medications were 10% more satisfied with their plans than those in a higher cost-sharing plan with a $11 copayment for brand-name medications.
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This presents an interesting dilemma for employers and managed care decision makers as copayment amounts for each tier in a 3-tier plan are continuing to increase between $5 and $15 more per year. Multi-tier copayment plans will generally most affect those persons who have the greater prescription drug needs, creating a paradox for policy makers and insurers. 33 These findings then raise important questions for the purchasers and providers of health care. If multi-tiered plans create greater dissatisfaction among managed care members and increase the cost burden for them, how will these attitudes influence prescription purchasing behavior? Will vulnerable individuals such as those with multiple or chronic disease states be confronted with decisions about which medications they can afford and which medications they will purchase when their copayments are increased? Second, will the long-term effects of these increased cost-sharing mechanisms result in unintended effects such as medication noncompliance and the failure to purchase prescription medications? And, will these effects, in turn, lead to a greater utilization of other medical care resources such as increased office and emergency room visits? Third, what are the characteristics of individuals that could be used to predict their prescription purchasing behavior in 3-tier plans? The findings of this study have shown that age, income, number of comorbidities, education, and the cost of care to the individual are some of the characteristics that could influence their prescription purchasing behavior.
■■ Limitations
There were several limitations to this study. First, the respondents appear to represent a self-selected group of individuals who are older, sicker, with greater cost sharing and, hence, were more eager to respond to the survey. It is possible that statistical differences found between the respondents and nonrespondents may be, in part, due to the large sample sizes employed in the study. If these differences do exist, the study findings may reflect the experiences of such a population and may not be generalizable to a larger, commercially insured population. Yet, these respondents are arguably those health plan members most affected by higher copay costs of prescription drugs, and the perceptions of these individuals may be of greater interest to managed care decision makers and employers. Second, the 2 groups (those in 2-and 3-tier plans, respectively) examined in this study were different with respect to certain characteristics, noticeably age, income, education, employment status, prescription cost-sharing amounts, and the cost of health plan premiums. To the extent possible, these differences were controlled for in the analyses, but it is possible that the responses obtained from these individuals on the various study measures may have been influenced by unmeasured differences between the 2 groups. Therefore, member attitudes about their prescription drug coverage may not entirely represent a response to the copayment amounts and access to medications that each group experienced with their respective pharmacy benefit plan but also may be a function of certain demographic and cost-sharing characteristics of each individual. The findings in this study should be considered in light of the differences that exist between the 2 groups.
Third, the survey data were cross-sectional; therefore, only the current association between pharmacy plan type and member attitudes could be determined, and the long-term effects of increased cost sharing on member satisfaction and loyalty of individuals in 3-tier plans could not be assessed. Additional research using a longitudinal design should be conducted that examines whether these member attitudes about 3-tier plans persist over time.
Finally, there may be other covariates, not included in the models, that may explain the low predictive value of the multivariate models used in the analyses. These may include other medical care utilization behavior such as number of physician visits. The analyses used in this study focused on demographic, cost of medical care, and the number of comorbidities that have shown to affect member satisfaction and related attitudes. 34 
■■ Conclusion
There are differences in patient perceptions regarding their prescription drug coverage. Specifically 2-tier plan members were more satisfied with their cost-sharing amounts than 3-tier members. Members in 2-tier plans were more satisfied with their prescription drug coverage, were more likely to recommend their plan to others, and were less likely to switch their current plans to obtain better prescription drug coverage compared to those in 3-tier plans. Older and sicker respondents and those with higher education and income appeared to have more positive attitudes toward their prescription drug coverage in general. The more cost sharing that members experienced for their prescription medications and health care premiums, the less favorable were their attitudes regarding their prescription drug coverage. Finally, while members expressed a willingness to buy lower-cost medications (e.g., a generic drug when prescribed a brand-name medication or a formulary alternative to a nonformulary medication), they were reluctant to pay more than $10 extra (in addition to their copayment) per month for medications in the higher tiers. These findings suggest that the cost of health care and prescription drug medications, in particular, have important effects on patient attitudes. The financial resources available to members (which may be a function of being older and having more education and higher incomes) and the number of chronic disease states may influence their attitudes toward their prescription drug coverage. Among the questions unanswered by this study is the effect of member attitudes on actual prescription-purchasing behavior of members.
